Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders.

Volcho KP, Laev SS, Ashraf GM, Aliev G, Salakhutdinov NF.

Curr Med Chem. 2018;25(39):5327-5346. doi: 10.2174/0929867324666170112101837. Review.

PMID:
28079000
2.

Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.

Fernández-Ruiz J, Romero J, Ramos JA.

Handb Exp Pharmacol. 2015;231:233-59. doi: 10.1007/978-3-319-20825-1_8. Review.

PMID:
26408163
3.

Type-2 cannabinoid receptors in neurodegeneration.

Bisogno T, Oddi S, Piccoli A, Fazio D, Maccarrone M.

Pharmacol Res. 2016 Sep;111:721-730. doi: 10.1016/j.phrs.2016.07.021. Epub 2016 Jul 20. Review.

PMID:
27450295
4.

Endocannabinoid system in neurodegenerative disorders.

Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S.

J Neurochem. 2017 Sep;142(5):624-648. doi: 10.1111/jnc.14098. Epub 2017 Jul 5. Review.

5.

Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.

Rui M, Rossino G, Coniglio S, Monteleone S, Scuteri A, Malacrida A, Rossi D, Catenacci L, Sorrenti M, Paolillo M, Curti D, Venturini L, Schepmann D, Wünsch B, Liedl KR, Cavaletti G, Pace V, Urban E, Collina S.

Eur J Med Chem. 2018 Oct 5;158:353-370. doi: 10.1016/j.ejmech.2018.09.010. Epub 2018 Sep 8.

PMID:
30223122
6.

Cannabinoids and neurodegenerative diseases.

Romero J, Orgado JM.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):440-50. Review.

PMID:
19839933
7.

Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.

Sonkusare SK, Kaul CL, Ramarao P.

Pharmacol Res. 2005 Jan;51(1):1-17. Review.

PMID:
15519530
8.

Neuroprotective properties of resveratrol and derivatives.

Richard T, Pawlus AD, Iglésias ML, Pedrot E, Waffo-Teguo P, Mérillon JM, Monti JP.

Ann N Y Acad Sci. 2011 Jan;1215:103-8. doi: 10.1111/j.1749-6632.2010.05865.x. Review.

PMID:
21261647
9.

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Fernández-Ruiz J, Moro MA, Martínez-Orgado J.

Neurotherapeutics. 2015 Oct;12(4):793-806. doi: 10.1007/s13311-015-0381-7. Review.

10.

New therapeutic strategy for Parkinson's and Alzheimer's disease.

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. Review.

PMID:
20586718
11.

Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.

Schmidt W, Schäfer F, Striggow V, Fröhlich K, Striggow F.

Neuroscience. 2012 Dec 27;227:313-26. doi: 10.1016/j.neuroscience.2012.09.080. Epub 2012 Oct 13.

PMID:
23069763
12.

Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2 R Ligands To Combat Neurodegenerative Disorders.

Dolles D, Nimczick M, Scheiner M, Ramler J, Stadtmüller P, Sawatzky E, Drakopoulos A, Sotriffer C, Wittmann HJ, Strasser A, Decker M.

ChemMedChem. 2016 Jun 20;11(12):1270-83. doi: 10.1002/cmdc.201500418. Epub 2015 Nov 9.

PMID:
26548365
13.

The influence of cannabinoids on generic traits of neurodegeneration.

Fagan SG, Campbell VA.

Br J Pharmacol. 2014 Mar;171(6):1347-60. doi: 10.1111/bph.12492. Review.

14.

Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia.

Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, Rodríguez-Pérez AI, Canela EI, Saura J, Lanciego JL, Labandeira-García JL, Saura CA, Fuxe K, Franco R.

Brain Behav Immun. 2018 Jan;67:139-151. doi: 10.1016/j.bbi.2017.08.015. Epub 2017 Aug 24.

PMID:
28843453
15.

Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.

Fernández-López D, Martínez-Orgado J, Nuñez E, Romero J, Lorenzo P, Moro MA, Lizasoain I.

Pediatr Res. 2006 Aug;60(2):169-73.

PMID:
16864698
16.

Cannabinoids.

López-Rodríguez ML.

Mini Rev Med Chem. 2005 Jul;5(7):607. No abstract available.

PMID:
16026306
17.

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA.

Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S91-6. doi: 10.1016/j.mce.2008.01.001. Epub 2008 Jan 17. Review.

PMID:
18291574
18.
19.

Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.

Michalska P, Buendia I, Del Barrio L, Leon R.

Curr Top Med Chem. 2017;17(9):1027-1043. doi: 10.2174/1568026616666160927154116. Review.

PMID:
27697052
20.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

Supplemental Content

Support Center